Roche Holding (RHO6) Price & Analysis
RHO6 Stock Chart & Stats
- Day’s Range
- EUR 54.03 - EUR 54.03
- 52-Week Range
- EUR 34.32 - EUR 54.20
- Previous Close
- EUR 54.20
- Volume
- 0
- Average Volume (3M)
- 65
- Market Cap
- EUR 348.56B
- Enterprise Value
- EUR 363.86B
- Total Cash (Recent Filing)
- EUR 9.70B
- Total Debt (Recent Filing)
- EUR 31.69B
- Price to Earnings (P/E)
- 26.3
- Beta
- 0.55
- Next Earnings
- Jan 28, 2027
- EPS Estimate
- 1.31
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.53%
Bulls Say, Bears Say
Bulls Say
High Profitability And Cash Generation
Roche combines high gross and operating margins with consistently positive free cash flow, indicating a strong economic model and meaningful internal funding capacity. This supports continued investment in research, launches and commercial infrastructure while providing resilience across the next several quarters.
Pipeline And Regulatory Momentum
Multiple priority reviews and positive late-stage trial results strengthen Roche’s ability to replenish revenue as established products mature. A broad, advancing pipeline can diversify future growth, improve launch visibility and reinforce the company’s position in complex therapeutic areas.
Expanding Medicines And Diagnostics Portfolio
Organic sales growth alongside progress toward new medicines and a differentiated Alzheimer’s blood test demonstrates ongoing portfolio development across both core businesses. These advances can broaden Roche’s addressable markets and strengthen future commercial opportunities beyond existing franchises.
Bears Say
Meaningful Leverage
Although leverage improved, Roche’s financing mix still provides less balance-sheet cushion than more conservatively funded peers. Higher debt relative to equity can constrain flexibility for acquisitions, shareholder distributions and research investment if earnings or cash generation weaken.
Uneven Revenue Growth
The uneven historical top-line pattern makes it harder to establish that recent growth will compound steadily. Volatility across years may reflect changing product demand and market conditions, requiring Roche to rely on successful launches and pipeline conversion to sustain momentum.
Competitive And Biosimilar Pressure
Biosimilar entry and competitive pressure in established franchises can erode sales and pricing power as products mature. These effects may persist beyond a single quarter, increasing the importance of replacement launches and successful lifecycle management to protect the revenue base.
Roche Holding News
RHO6 FAQ
What was Roche Holding’s price range in the past 12 months?
What is Roche Holding’s market cap?
When is Roche Holding’s upcoming earnings report date?
How were Roche Holding’s earnings last quarter?
Is Roche Holding overvalued?
Does Roche Holding pay dividends?
What is Roche Holding’s EPS estimate?
How many shares outstanding does Roche Holding have?
What happened to Roche Holding’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Roche Holding?
What is the TipRanks Smart Score and how is it calculated?
Roche Holding Stock Smart Score
Company Description
Roche Holding
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Thomas Schinecker
- Employees
- 103,249
- Website
- www.roche.com
- Address
- Grenzacherstrasse 124, Basel, BS, 4070, CH
Roche Holding (RHO6) Earnings & Revenues
RHO6 Company Deck
RHO6 Earnings Call
Earnings Call SentimentPositive
Overall the call conveyed a positive operating and pipeline momentum despite identifiable headwinds. Roche reported strong profitability (core op profit +10%, margin expansion), solid organic growth in Pharma, multiple regulatory wins (5 priority reviews) and major diagnostics and R&D milestones (AXELIOS launch, CE marks, strategic M&A). Offsetting items include China pricing reform and a weak respiratory season hitting Diagnostics, currency translation pressures, a near‑term net debt increase (timing effects) and some competitive/biosimilar pressure in specific franchises. On balance, the operational and pipeline achievements materially outweigh the manageable challenges described.
View all DE:RHO6 earnings summariesRHO6 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |